Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Who will benefit the most from adjuvant IO in melanoma?

Jason Luke • 2 Jun 2023
ASCO 2023
Melanoma Skin Cancer

Jason Luke, MD, FACP, University of Pittsburgh, Pittsburgh, PA, discusses unanswered questions regarding the use of adjuvant immunotherapy (IO) in patients with melanoma. A large proportion of patients will receive adjuvant immunotherapy, which leads to overtreatment. Additional biomarkers are needed to effectively find patients who will benefit the most from treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So probably the big issue surrounding adjuvant therapy in general, but certainly in melanoma is the risk of population overtreatment...

So probably the big issue surrounding adjuvant therapy in general, but certainly in melanoma is the risk of population overtreatment. And what we need to think about moving forward in the field are biomarker strategies to try to figure out who really needs the treatment versus who could we defer and just monitor over time.

Read more...

More from Jason Luke

SUPRAME: a PRAME-specific TCR-T cell therapy in cutaneous melanoma
2:09
SUPRAME: a PRAME-specific TCR-T cell therapy in cutaneous melanoma
Jason Luke • 23 May 2025
IGNYTE-3: vusolimogene oderparepvec and nivolumab in cutaneous melanoma
1:39
IGNYTE-3: vusolimogene oderparepvec and nivolumab in cutaneous melanoma
Jason Luke • 23 May 2025
TeLuRide-006: first-line EIK1001 and pembrolizumab in advanced melanoma
1:51
TeLuRide-006: first-line EIK1001 and pembrolizumab in advanced melanoma
Jason Luke • 23 May 2025
How can vusolimogene oderparepvec improve outcomes in melanoma?
1:15
How can vusolimogene oderparepvec improve outcomes in melanoma?
Jason Luke • 23 May 2025

Related Videos

BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
1:45
BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
Kalijn Bol • 31 May 2026
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
1:08
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
Kalijn Bol • 31 May 2026
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
1:02
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
Kalijn Bol • 31 May 2026
The future of personalized and off-the-shelf mRNA vaccines in melanoma
1:02
The future of personalized and off-the-shelf mRNA vaccines in melanoma
James Smithy • 31 May 2026
The content of VJOncology is intended for healthcare professionals